Question to the Department of Health and Social Care:
To ask His Majesty's Government whether the Medicines and Healthcare products Regulatory Agency intends to include any mention of post-SSRI sexual dysfunction in the Direct Healthcare Professional Communication that will be sent out after the recent expert working group on antidepressants.
The Direct Healthcare Professional Communication (DHPC) outlining the new safety measures to improve communication about the risk of suicidal thoughts and behaviours and persistent sexual dysfunction was distributed electronically by MedicinesUK, on behalf of marketing authorisation holders, to healthcare professionals across the United Kingdom on 23 October, with hard copies subsequently being sent by post.
The DHPC highlights the addition of information on post-SSRI sexual dysfunction to the patient information leaflets for certain antidepressants. It provides links to further information about the review in the Medicines and Healthcare products Regulatory Agency’s bulletin Drug Safety Update, published on 15 October, a copy of which is attached.